Pancreatic Cancer Research

ResearcherUniversity of MiamiNo recent work listed

Sulagna Banerjee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2338-1662; OpenAlex author ID A5088154323; NIH RePORTER profile ID 10560104. Sources: OpenAlex.

Their work

Papers
36 (first author 3, last author 13)
Trials
0
Grants
1
Labs led
2
Collaborators
53
Papers, trials and grants by year

2012: 2 papers · 2013: 3 papers · 2014: 3 papers · 2015: 2 papers · 2016: 6 papers · 2017: 4 papers · 2018: 4 papers, 1 grant · 2019: 3 papers · 2020: 5 papers · 2021: 3 papers · 2022: 1 paper

Papers 36

  1. Obesity enriches for tumor protective microbial metabolites and treatment refractory cells to confer therapy resistance in PDAC. Last author DOI 10.1080/19490976.2022.2096328↗
  2. An Immunocompetent Model of Pancreatic Cancer Resection and Recurrence. Co-author DOI 10.1007/s11605-020-04681-9↗
  3. Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-20-2562↗
  4. Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0083↗
  5. Learning From Gender Disparity: Role of Estrogen Receptor Activation in Coping With Pancreatic Cancer. First author DOI 10.1016/j.jcmgh.2020.07.009↗
  6. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. Co-author DOI 10.1084/jem.20190354↗
  7. Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of pancreatic cancer. Co-author DOI 10.1093/carcin/bgz116↗
  8. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. Last author DOI 10.1172/jci127515↗
  9. Type 2 diabetes induced microbiome dysbiosis is associated with therapy resistance in pancreatic adenocarcinoma. Last author DOI 10.1186/s12934-020-01330-3↗
  10. Targeting tumor intrinsic metabolic node in pancreatic cancer causes tumor regression,remodels extracellular matrix and sensitizes to anti-PD1 therapy Co-author DOI 10.1016/j.pan.2019.05.430↗
  11. ER stress sensor, glucose regulatory protein 78 (GRP78) regulates redox status in pancreatic cancer thereby maintaining "stemness". Last author DOI 10.1038/s41419-019-1408-5↗
  12. O-GlcNAc modification of Sox2 regulates self-renewal in pancreatic cancer by promoting its stability. Last author DOI 10.7150/thno.32615↗
  13. GRP78-mediated antioxidant response and ABC transporter activity confers chemoresistance to pancreatic cancer cells. Last author DOI 10.1002/1878-0261.12322↗
  14. Metastasis and chemoresistance in CD133 expressing pancreatic cancer cells are dependent on their lipid raft integrity. Last author DOI 10.1016/j.canlet.2018.09.028↗
  15. A Theranostic Approach to Target Gastrin in Pancreatic Cancer. Co-author DOI 10.1016/j.jcmgh.2018.04.002↗
  16. Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression. Co-author DOI 10.1158/0008-5472.can-17-2320↗
  17. Modulation of post-translational modifications in β-catenin and LRP6 inhibits Wnt signaling pathway in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.11.026↗
  18. Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters. Last author DOI 10.1016/j.pan.2016.12.010↗
  19. Inhibition of Sp1 prevents ER homeostasis and causes cell death by lysosomal membrane permeabilization in pancreatic cancer. Last author DOI 10.1038/s41598-017-01696-2↗
  20. Inhibition of hypoxic response decreases stemness and reduces tumorigenic signaling due to impaired assembly of HIF1 transcription complex in pancreatic cancer. Last author DOI 10.1038/s41598-017-08447-3↗
  21. Control of Apoptosis in Treatment and Biology of Pancreatic Cancer. Co-author DOI 10.1002/jcb.25284↗
  22. A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies. Co-author DOI 10.1007/s11605-015-2985-y↗
  23. Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer. Co-author DOI 10.1007/s11605-015-3000-3↗
  24. Inhibition of NF-kappa B pathway leads to deregulation of epithelial-mesenchymal transition and neural invasion in pancreatic cancer. Co-author DOI 10.1038/labinvest.2016.109↗
  25. Evolution of novel therapeutic options for pancreatic cancer. Last author DOI 10.1097/mog.0000000000000298↗
  26. Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-1155↗
  27. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer. Last author DOI 10.1186/s12943-015-0470-6↗
  28. CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. First author DOI 10.18632/oncotarget.3228↗
  29. Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway. Co-author DOI 10.1016/j.canlet.2014.03.016↗
  30. Triptolide activates unfolded protein response leading to chronic ER stress in pancreatic cancer cells. First author DOI 10.1152/ajpgi.00466.2013↗
  31. CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide. Co-author DOI 10.1158/1078-0432.ccr-13-2947↗
  32. Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1. Co-author DOI 10.1074/jbc.m113.500983↗
  33. Triptolide induces the expression of miR-142-3p: a negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. Co-author DOI 10.1158/1535-7163.mct-12-1231↗
  34. miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death. Co-author DOI 10.1186/1476-4598-12-105↗
  35. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Co-author DOI 10.1126/scitranslmed.3004334↗
  36. MUC1c regulates cell survival in pancreatic cancer by preventing lysosomal permeabilization. Co-author DOI 10.1371/journal.pone.0043020↗

Grants 1

  1. Functional Significance of CD133 in Pancreatic Cancer R01CA184274↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ashok Kumar Saluja · 31 shared papers, 2012–2021 · strength 2.38
  2. Vikas Dudeja · 25 shared papers, 2012–2021 · strength 1.69
  3. Vineet Kumar Gupta · 12 shared papers, 2017–2022 · strength 1.20
  4. Kousik Kesh · 9 shared papers, 2018–2022 · strength 0.95
  5. Nikita Sharma · 10 shared papers, 2017–2021 · strength 0.87
  6. Bhuwan Giri · 10 shared papers, 2016–2021 · strength 0.80
  7. Patricia Dauer · 9 shared papers, 2016–2019 · strength 0.72
  8. Alice Nomura · 10 shared papers, 2014–2018 · strength 0.68
  9. Santanu Banerjee · 6 shared papers, 2018–2022 · strength 0.67
  10. Selwyn Maurice Vickers · 11 shared papers, 2012–2019 · strength 0.53
  11. Nipun B. Merchant · 4 shared papers, 2020–2022 · strength 0.49
  12. Roberto Méndez · 3 shared papers, 2020–2022 · strength 0.41
  13. Shrey Modi · 5 shared papers, 2016–2021 · strength 0.38
  14. Rohit Chugh · 7 shared papers, 2012–2016 · strength 0.32
  15. Anthony R. Ferrantella · 3 shared papers, 2019–2021 · strength 0.31
  16. Olivia McGinn · 5 shared papers, 2013–2017 · strength 0.30
  17. Kaustav Majumder · 4 shared papers, 2016–2017 · strength 0.26
  18. Beatriz Mateo-Victoriano · 2 shared papers, 2021–2022 · strength 0.25
  19. Sundaram Ramakrishnan · 3 shared papers, 2016–2021 · strength 0.23
  20. Florencia M. McAllister · 2 shared papers, 2020 · strength 0.20
  21. Jashodeep Datta · 1 shared paper, 2022 · strength 0.15
  22. Xianda Zhao · 2 shared papers, 2016–2018 · strength 0.14
  23. Vrishketan Sethi · 1 shared paper, 2021 · strength 0.11
  24. Austin R. Dosch · 1 shared paper, 2021 · strength 0.11
  25. Iago De Castro Silva · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.